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ABBREVIATIONS
MAT Medically assisted treatment
MDI Mental Development Index
NAS Neonatal abstinence syndrome
PDI Psychomotor Development
Index
VEP Visual evoked potential
WMD Weighted mean difference
AIM To systematically review and meta-analyse studies of neurodevelopmental outcome of
children born to mothers prescribed methadone in pregnancy.
METHOD MEDLINE, Embase, and PsycINFO were searched for studies published from 1975 to
2017 reporting neurodevelopmental outcomes in children with prenatal methadone exposure.
RESULTS Forty-one studies were identified (2283 participants). Eight studies were amenable
to meta-analysis: at 2 years the Mental Development Index weighted mean difference of
children with prenatal methadone exposure compared with unexposed infants was 4.3 (95%
confidence interval [CI] 7.24 to 1.63), and the Psychomotor Development Index weighted
mean difference was 5.42 (95% CI 10.55 to 0.28). Seven studies reported behavioural
scores and six found scores to be lower among methadone-exposed children. Twelve studies
reported visual outcomes: nystagmus and strabismus were common; five studies reported
visual evoked potentials of which four described abnormalities. Factors that limited the
quality of some studies, and introduced risk of bias, included absence of blinding, small
sample size, high attrition, uncertainty about polydrug exposure, and lack of comparison
group validity.
INTERPRETATION Children born to mothers prescribed methadone in pregnancy are at risk of
neurodevelopmental problems but risk of bias limits inference about harm. Research into
management of opioid use disorder in pregnancy should include evaluation of childhood
neurodevelopmental outcome.
Opioid use, both prescribed and illicit, has been increasing
globally since 2007. Past-year prevalence of heroin use has
almost doubled since 2007, and the rate of increase is
higher among women compared with men. In the USA,
the average rate of past-year heroin use between 2013 and
2015 was 2.0 per 1000 women,1 and since 2000 there has
been an almost fivefold increase in the prevalence of
neonatal abstinence syndrome (NAS), a drug withdrawal
syndrome commonly used as a proxy for opioid exposure
during pregnancy.2 It is estimated that in the current opi-
oid crisis up to 14.4% of pregnant women have opioid
prescriptions dispensed during pregnancy.3
Pregnant women who use heroin are recommended
medically assisted treatment (MAT) with an opioid substi-
tute such as methadone as part of a comprehensive antena-
tal care plan because it is associated with improved use of
antenatal services, reduced use of heroin during pregnancy,
and reduced risk of preterm delivery, when compared with
no treatment.4–9 Fetal benefits of MAT include improved
growth7,10 and less risk of intrauterine death.8
Methadone is a synthetic long acting l-opioid agonist
which freely crosses the placenta; despite the potential for
methadone to affect the developing fetal brain, this treat-
ment was introduced into practice without a randomized
controlled study of childhood neurodevelopmental out-
come. Preclinical studies suggest that exogenous opioids
may exert pleiotropic harmful effects on the central ner-
vous system,11–13 and diffusion magnetic resonance imag-
ing studies show that the tract tissue microstructure of
white matter (fractional anisotropy) is altered in neonates
exposed prenatally to methadone.14,15 Improved under-
standing of the neurodevelopmental outcome of children
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born to opioid-dependent mothers and exposed prenatally
to methadone is essential to inform management of their
mothers during pregnancy.16–18 The issue is prescient
because the optimal methadone dose regimen is uncer-
tain,19 and alternative opioids such as buprenorphine may
have a different risk profile for neonatal outcome,16,17,20
leading to equipoise about the optimal MAT strategy.
The aims of this study were to perform a systematic
review of published literature on childhood neurodevelop-
mental outcomes after prescription of maintenance metha-
done in pregnancy, and to undertake a meta-analysis of
studies that used a common assessment tool.
METHOD
The study protocol was registered with the international
prospective register of systematic reviews (PROSPERO),
registration number CRD42017063987 (https://www.crd.
york.ac.uk/prospero/). Methodology is reported according
to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement.21
We included all studies that reported neurodevelopmen-
tal outcome, including visual development, of children
whose opioid-dependent mothers were prescribed metha-
done during pregnancy. There was no language restriction.
Exclusion criteria were prescription of alternative opioid
substitutes during pregnancy and studies reporting only
neonatal neurodevelopment.
Two reviewers (VJM, RH) independently searched
MEDLINE, Embase, and PsycINFO for studies published
between 1975 and 2017. Medical Subject Headings terms
used were ‘methadone’ and ‘prenatal’ or ‘prenatal expo-
sure’ or ‘prenatal drug exposure’ or ‘prenatal exposure
delayed effects’ or ‘in utero’. Bibliographies of primary
studies and review articles meeting the inclusion criteria
were searched manually to identify further eligible studies.
Three reviewers (VJM, RH, HM) independently
screened titles and abstracts to identify potentially eligible
studies. Where necessary to determine eligibility, full text
was retrieved and reviewed. Duplication was avoided if it
was clear that the same cohort was reported in two publi-
cations; where more than one publication for a study was
retrieved, only the report that contained the maximum data
points was included.
Four reviewers (VJM, RH, HM, JPB) independently
extracted data from included studies using a standardized
template. Extracted information included study setting,
design, population and participant demographics, details of
methadone exposure if available, control conditions,
recruitment and completion rates, age at outcome mea-
surement, assessment tool, and outcome of assessment.
Data were extracted from each study by two reviewers
independently, and templates were combined to ensure
complete data collection. Disagreements were resolved
through discussion.
A quality assessment instrument was developed using the
Grading of Recommendations Assessment Development
and Evaluation Guidelines22–24 to provide a structured
scoring system that aimed to describe quality and sources
of bias in studies of neurodevelopment after prenatal drug
exposure. It incorporated objective criteria about study
design, sample size and characteristics, use of validated
outcome measures, risk of bias (blinding, confounding,
attrition), and data analysis. Each study was assessed inde-
pendently by two reviewers (VJM, JPB) and scored as good
(A, 6.5–8), intermediate (B, 3.5–6), or poor (C, 1–3) quality
(Table SI, online supporting information).
Statistical analysis
Where studies used the same assessment tool for any out-
come domain, quantitative data were pooled in random
effects meta-analysis using R software, version 3.2.2 (K
Hornik; R Foundation for Statistical Computing, Vienna,
Austria; https://cran.r-project.org/) with mean difference
weighted by the inverse of the variance.25 Effect sizes were
expressed as weighted mean differences (WMD) and their
95% confidence intervals (CI). For longitudinal studies,
data for assessments at 6 months and at 2 years were anal-
ysed. Heterogeneity was assessed using the standard I2 and
s statistics and graphically using forest plots. Where statis-
tical pooling was not possible, data were collated in tables
for outcomes across two domains (neurodevelopmental and
visual development), and statements generated to represent
the body of literature reviewed.
RESULTS
Characteristics of included studies
Forty-one eligible studies were identified, including a total
of 1441 methadone-exposed children and 842 unexposed
children (Fig. S1, online supporting information). Twenty-
nine studies reported neurodevelopmental outcome (1247
methadone-exposed vs 740 unexposed children), eight of
which were amenable to meta-analysis; 12 reported visual
outcome (275 methadone-exposed vs 128 unexposed).
There were no randomized trials.
Only one study fulfilled criteria for good quality;26 26
(63%) studies were intermediate and 14 (34%) were poor
quality (Table SI). Study deficiencies included lack of
blinding, small sample size, high attrition rates, and lack of
comparison group validity. Twenty-four of 41 studies
reported information about polydrug use during preg-
nancy, and 20 studies provided information about metha-
done dose exposure.
Thirty-three of 41 studies reported infants receiving
pharmacological treatment of NAS; in 19 of these the
treatment regimen was described, with the most frequently
What this Study Adds
• Children born to opioid-dependent mothers prescribed methadone are at risk
of neurodevelopmental impairment.
• Exposed infants have lower Mental Development Index and Psychomotor
Development Index scores than unexposed children.
• Atypical visual evoked potentials, strabismus, and nystagmus have increased
prevalence.
• Estimates of impairment may be biased by intermediate to poor quality evi-
dence.
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used drugs being morphine, phenobarbital, benzodi-
azepines, or a combination. Sixteen studies stated that
infants born preterm were included, while only seven
explicitly excluded infants born before 36 weeks’ gestation.
In 18 studies, it could not be determined whether infants
born preterm were included.
Neurodevelopmental outcome
Of 29 studies reporting neurodevelopmental outcome, 15
used the original Bayley Scales of Infant Development.27
Five of these 15 studies had no comparison individuals,28–32
one did not report a measure of variance,33 and one
assessed children at 9 months only;34 leaving eight studies
that were eligible for meta-analysis of neurodevelopmental
outcome based on the Bayley Scales of Infant Development
(Table I).
Five studies reported Mental Development Index (MDI)
at 6 months of age,35–39 and four of these reported Psy-
chomotor Development Index (PDI)35–37,39 (Fig. 1). Stud-
ies were all of intermediate quality with attrition rates
ranging from 31% to 70%; three studies described mater-
nal methadone doses, and gestational age was variably
reported. For both MDI and PDI at 6 months, the differ-
ence in exposed versus non-exposed infants was marginal
and 95% CIs included the possibility of no difference:
MDI, WMD of 1.56 (95% CI 4.98 to 1.87; Fig. 1a);
PDI, WMD of 2.46 (95% CI 6.75 to 1.82; Fig. 1b).
Seven studies reported MDI at 2 years of age,36–42 four
of which reported PDI36,37,39,42 (Table I). All seven studies
were rated intermediate quality, with attrition rates ranging
from 18% to 84%; maternal methadone dose was variably
reported; and where polydrug use was reported (five of
seven studies), this ranged from 56% to more than 90% of
mothers. The gestational age of participants was not stated
in four studies.38,40–42 Five studies reported rates of NAS
between 67% and 92%; and no study described treatment
for NAS. Compared with non-exposed children, metha-
done exposure was associated with lower MDI, WMD of
4.43 (95% CI 7.24 to 1.63; Fig. 2a), and lower PDI,
WMD of PDI 5.42 (95% CI 10.55 to 0.28; Fig. 2b).
Of the remaining 21 neurodevelopmental studies, 13
were rated as having intermediate quality and eight as poor
quality. Infant Behavior Record was reported in two stud-
ies: Marcus et al. reported poorer motor performance at 4
months in 15 methadone-exposed infants compared with
23 unexposed infants;43 and Wilson et al.34 matched 33
methadone-exposed infants with 55 unexposed infants for
maternal age, ethnicity, socio-economic status, and marital
status, and reported poorer fine motor coordination, less
attentiveness, and lower motor scores on the Bayley Scales
of Infant Development at 9 months of age, but no differ-
ence in cognitive scores. Schneider and Hans reported no
difference in focused attention during free play at 24
months between 30 exposed and 44 unexposed toddlers.44
Suffet et al.30 reported MDI and PDI in the normal
range at 1 year, with females performing better than males
(MDI mean 108.8 vs 102.7, p<0.05; PDI mean 102.3 vs
95.7, p<0.05). This association persisted for cognition up
to 2 years of age (MDI 99.2 vs 82.0, p<0.01). Bier et al.45
reported MDI scores in the normal range at 4 months of
age, in a cohort of 165 methadone-exposed infants, with
no difference between those infants exposed prenatally to
either low dose (<100mg/d) or high dose (≥100mg/d)
methadone.
At 6 months of age, using the Griffiths Scales of Mental
Development, McGlone et al.46 noted reduced median
scores across all domains which persisted after adjustment
for prenatal alcohol exposure and maternal smoking. This
study included 81 methadone-exposed infants and 26 non-
drug-exposed infants, matched for gestation and socio-eco-
nomic status. Scores were also lower for infants who had
been treated for NAS (median general quotient 95 vs 99,
p<0.008). Bunikowski et al.47 reported reductions in quo-
tients for two subscales (hearing and speech; intellectual per-
formance) at 1 year of age in a case series of 18 prenatally
exposed infants compared with 42 unexposed children.
Twelve studies evaluated children older than 2 years
using a range of assessment tools (Table II). Participants
included 323 methadone-exposed children and 321 unex-
posed children.
Six out of 10 studies measuring cognitive outcomes
reported no difference between methadone-exposed and
unexposed children,37,38,41,48–50 and four studies reported
lower cognitive performance in methadone-exposed chil-
dren at 2 years 6 months,39 3 years,51 3 years 6 months,52
4 years 6 months,52 5 years 6 months,52 and 8 years 6
months53 respectively. The Reynell Developmental Lan-
guage Scales were used in two studies (93 methadone-
exposed vs 76 unexposed children) at 3 years51 and at 4
years;52 both reported reduced performance in expressive
and comprehensive language. Of the seven studies assessing
behaviour, six reported more behavioural problems in
methadone-exposed children than in unexposed chil-
dren.41,50–52,54,55 Details of all studies reporting childhood
neurodevelopmental outcome after prenatal methadone
exposure are summarized in Table SII (online supporting
information).
Visual development and function
Twelve studies reported visual outcomes, five of which
measured visual evoked potentials (VEPs; Table SIII,
online supporting information). The VEP studies consisted
of a total of 143 methadone-exposed and 103 unexposed
children, with one rated poor quality, three rated interme-
diate, and one rated good quality.
In two different cohorts, flash VEPs at 1 day to 4 days
after birth were more frequently absent or immature and
were smaller on average in methadone-exposed infants
compared with non-exposed newborns.56,57 At 4 months58
and at 6 months of age,26 pattern-reversal and pattern-
onset VEP abnormalities persisted in methadone-exposed
infants. One follow-up study of 10 3-year-old children pre-
viously tested at 4 months found no group difference in
pattern-reversal VEP peak times.59
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A further six case series have described abnormal visual
outcomes in a total of 108 methadone-exposed children60–65
(Table SIV, online supporting information). All six studies
were rated as having poor quality evidence because they
did not have comparison groups and did not correct for
confounders owing to their observational design. However,
collectively they describe common visual abnormalities,
nystagmus (50 out of 108) and strabismus (51 out of 108),
which may occur together (22 out of 108 cases). Nystag-
mus in all described cases was horizontal and either jerk or
pendular in waveform.
In a case–control study of 100 methadone-exposed
infants, 81 of whom were followed up at 6 months of age,
abnormal visual outcomes were present in 40% of metha-
done-exposed children (nystagmus nine out of 81 cases,
strabismus 20 out of 81 cases; both five out of 81) com-
pared with two out of 26 non-drug exposed infants
matched for gestation and socio-economic status.26 One
intermediate quality study of methadone-exposed 4-year-
old children reported reduced visual selective attention in
methadone-exposed children compared with unexposed
children.66
DISCUSSION
This systematic review of neurodevelopmental and visual
outcomes of children born to opioid-dependent mothers
prescribed methadone in pregnancy has synthesized data
from 41 studies (1441 children whose mothers were pre-
scribed methadone and 842 children whose mothers were
not prescribed methadone during pregnancy). In the meta-
analysis, we found that point estimates of MDI and PDI in
children exposed to prenatal methadone compared with
children whose mothers were not prescribed methadone
are reduced at 6 months of age, and by 2 years the 95%
CIs of these estimates make the possibility of no group dif-
ference in MDI and PDI unlikely. The emergence of diffi-
culties as children grow older is well-recognized after
complications during the perinatal period and is likely to
reflect the ontogeny of higher-order functions through
childhood. The finding of behavioural problems in six out
of seven studies that measured this domain, and lower cog-
nitive performance in four out of 10 studies that reported
outcome after 2 years, suggests that children of opioid-
dependent mothers prescribed methadone may be at
increased risk of longer-term problems.
An association between prenatal methadone exposure
and atypical visual development has been described, with
significant differences in VEPs in infancy and childhood,
reflecting altered visual pathways.56,58 McGlone et al.,26 in
their cohort of 81 methadone-exposed and 29 unexposed
infants at 6 months of age, describe a methadone-attributa-
ble risk of abnormal visual assessment of 80%, after cor-
recting for excess prenatal alcohol exposure. The
prevalence of childhood strabismus and nystagmus in the
methadone-exposed population is higher than expected,
which suggests that disorders of childhood visual function,
as well as altered electrophysiological measures, are associ-
ated with prenatal methadone exposure.
Our findings are consistent with a recent meta-analysis
of five studies of infants and preschool children exposed to
chronic intrauterine illicit heroin and/or prescribed metha-
done, which reported neurobehavioural impairment in the
opioid-exposed group.67,68 Our data provide additional
information by focusing on studies of women prescribed
methadone, analysis of studies that reported a wide range
of outcomes including visual development, and inclusion
criteria designed to achieve maximum representation of the
target population. Specifically, because use of prescribed
and non-prescribed drugs and tobacco is common among
pregnant women prescribed methadone (but ascertainment
and reporting of polydrug exposure in studies is variable),69
and because our purpose was to determine outcomes of
methadone-exposed children rather than to investigate cau-
sation, we took a pragmatic approach and did not attempt
to exclude on the basis of polydrug use.
The data are also consistent with the observation that
fractional anisotropy is reduced throughout the white mat-
ter skeleton of neonates born to mothers who were pre-
scribed methadone,15 because neonatal fractional
anisotropy is associated with later neurodevelopmental
impairment.70,71 More broadly, these results contribute to
an emerging literature suggesting that exposure of the
brain to psychoactive drugs during the perinatal period
may modify its development.72,73
A strength of this work is its pragmatic and systematic
approach to summarizing childhood neurodevelopmental
outcome after prescribed prenatal methadone exposure.
We excluded studies of neonatal neurodevelopment to pre-
vent confounding by NAS, and we excluded studies of
alternative opioid substitutes to derive maximum inference
about methadone.
However, limitations of included studies mean that the
risk of impairment in children whose mothers were pre-
scribed methadone may be biased. In particular, compar-
ison groups were often poorly described beyond the
definition of ‘non-opioid exposed’, with inadequate control
for socio-economic status, or environmental factors, mak-
ing it difficult to know who the methadone-exposed chil-
dren were being compared with. Reporting of maternal
methadone dosing and polydrug or alcohol use was vari-
able and therefore it was difficult to obtain an accurate
exposure profile of included children; only one study exam-
ined prenatal exposure in all infants in detail using exten-
sive toxicology.57 Finally, only 15 of the 41 studies were
published in the past decade, which might affect applica-
tion of results to contemporary populations because pat-
terns of drug misuse change over time and strategies for
MAT of opioid use disorder in pregnancy have evolved.
For example, the dose of methadone prescribed for MAT
in current practice is typically higher than that reported in
historical studies. Further study of contemporary popula-
tions is required to determine the neurodevelopmental and
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Table II: Summary of 12 studies reporting neurodevelopmental outcomes in children beyond age 2y
Study
Quality
ratinga
Methadone-
exposed Unexposed Ageb Drug informationc
Assessment
tool
Main findingsd (results appear as
methadone vs unexposed)
Strauss
et al.48
B 31 27 5y No information MSCA 86.8 (13.3) vs 86.2 (16.2), ns
Lifschitz
et al.49
B 26 41 3y
5mo
95% taking heroin or
psychoactive drugs
MSCA 90.4 (13) vs 89.4 (10.8), ns
Rosen and
Johnson37
B 39 21 3y 42 (mean of original
cohort)
M-P 44.6 (2.1) vs 46.3 (2.3) ns
Davis and
Templer53
C 12 28 8y
6mo
No information WISC-R 89.58 (10.32) vs 96.32 (8.72) no
p-value
Wilson41 B 26 41 3–5y No information MSCA (GCI)
Survey and
school
reports
IQ testing
GCI: 90.4 (13.0) vs 89.4 (10.8) ns
IQ 1–2 SD below norm 8% vs 5%,
language disability 8% vs 5%,
special education needs 16% vs
19%, behavioural problems 75% vs
48%, psychiatric referral 16% vs 5%
12 12 6–11y
Kaltenbach
and
Finnegan38
B 27 17 3y
6mo–
4y
6mo
Mean dose 38.42 MSCA (GCI) GCI: 106.5 (12.96) vs 106.05 (13.10),
t=0.11
Sandberg
et al.54
B 30 16 5–8y 39.5 (males), 38.7
(females)
Original cohort, 68%
polydrug use; 15%
moderate to heavy
alcohol intake
CGPQe
CBAQe
(males
only)
Methadone-exposed males showed
more feminine game play than
comparison males (p<0.04)
van Baar39 B 19 34 2y
6mo
No information BSID (MDI,
PDI, NDI)
WWPAe
MDI 86 (15) vs 98 (16) p<0.05
PDI 102 (16) vs 100 (18) ns
NDI 93 (16) vs 102 (22)
WWPA 1.62 (1.03–2.66) vs 1.64
(1.28–2.52) ns
de Cubas and
Field50
B 20 20 8y
6mo
No drug information.
‘Moderate alcohol
use’
SBIS
KABC-A
RATC
CBCLe
SBIS: 97.6 vs 98.1, ns
KABC-A: 98.8 vs 102.4, no p-value
RATC: methadone-exposed scored
higher on anxiety, aggression,
rejection, maladaptive outcome,
p<0.01 for all
CBCL: more behaviour problems
p<0.05
van Baar and
de Graaff52
B 23 32 3y
6mo
Polydrug use; 16 out
of 35 heroin and
cocaine, only 2 out
of 35 solely
methadone
SON-IQ at
3y 6mo;
RDLSC and
RDLSE at
4y;
RAKIT at 4y
6mo and
5y 6mo;
IBR at
3y 6mo
(n=22),
4y 6mo
(n=23), 5y
6mo (n=22)
SON-IQ: 99 (9) vs 109 (11), p<0.01
RDLSC: 46 (6) vs 52 (6), p<0.01
RDLSE: 46 (9) vs 50 (6), p<0.05
RAKIT 4y 6mo: 85 (11) vs 103 (15),
p<0.01
RAKIT 5y 6mo: 90 (12) vs 102 (17),
p<0.05
IBR: results median (range):
3y 6mo: free of fear: 9 (4–9) vs 6.5 (2
–9), p<0.05; activity level: 6 (3–9) vs
5 (2–9), p<0.05; attention: 5 (1–7) vs
5.5 (1–9) p<0.05; fine motor: 3 (1–5)
vs 3 (1–5), p<0.05
4y 6mo: cooperation: 6 (2–9) vs 7
(3–9), p<0.01; endurance: 4 (2–9) vs
6 (1–9), p<0.01; attention: 8 (2–9) vs
5 (2–8), ns
5y 6mo: cooperation: 6 (1–9) vs 8
(4–9), p<0.01; free of fear: 8 (2–9) vs
9 (5–9), ns; attention: 5 (2–8) vs 5
(3–9), ns
26 32 4y
23 31 4y
22 30 6mo
5y
6mo
Hunt et al.51 B 67 44 3y No information SBIS;
VSMS;
MSCA;
RDLSC and
RDLSE
SBIS: 99.9 (15.1) vs 107.5 (13.4),
p<0.01
VSMSL: 38.4 (8.1) vs 46.1 (7.7),
p<0.05
MSCA: 49.5 (8.7) vs 53.9 (8.3),
p<0.05
RDLSC: 42.4 (11.6) vs 49.2 (11.4),
p<0.05
RDLSE: 35.5 (7.9) vs 42.8 (12.8),
p<0.05
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visual outcomes of children born to opioid-dependent
mothers.
Improved understanding of the effects of prenatal opioid
use disorder and its treatment, including the use of alternative
substitutes, has been identified as a research priority.74
Buprenorphine has been evaluated as an opioid substitute in
pregnancy. Although less severe NAS, improved growth,
shorter hospital stay, and longer gestation are all reported in
buprenorphine-exposed compared with methadone-exposed
infants,16,75–77 a recent Cochrane review concluded that there
are insufficient data to establish whether buprenorphine is
equivalent for all maternal outcomes, including adherence to
treatment.18 Furthermore, confounding by indication could
explain improved neonatal outcomes in buprenorphine
groups.17 Therefore, there remains clinical equipoise about
the safest opioid substitute for mother and child.
The data presented highlight that being born to an opi-
oid-dependent mother who has been prescribed
Table II: Continued
Study
Quality
ratinga
Methadone-
exposed Unexposed Ageb Drug informationc
Assessment
tool
Main findingsd (results appear as
methadone vs unexposed)
Konijnenberg
et al.55
B 24 0 4y Mean 85.96f;
polydrug use in 40%
(illegal drug use),
25% alcohol
CBCLe Scores >55 on aggressive behaviour
and withdrawn behaviour
aQuality rating: A, good; B, intermediate; C, poor; based on modified Grading of Recommendations Assessment Development and Evalua-
tion criteria (Table SI, online supporting information). bAge expressed in months (mo) or years (y). cDrug information includes mean daily
methadone dose (in milligrams) and information on maternal polydrug use (defined as methadone plus any other drug use during preg-
nancy, excluding tobacco), where these are reported. Unless otherwise stated, all information in this column refers to methadone-exposed
group only. dScores are presented as mean values (standard deviation) unless otherwise stated. eQuestionnaire completed by parent or
caregiver. fMean methadone dose excludes outlier daily dose of 660mg methadone. MSCA, McCarthy Scales of Childhood Abilities; ns,
not significant; M-P, Merril-Palmer Scale; WISC-R, Wechsler Intelligence Scale for Children–Revised; GCI, general cognitive index (used in
the MSCA); SD, standard deviation; CGPQ, Child Game Participation Questionnaire; CBAQ, Child Behavior Attitude Questionnaire; BSID,
Bayley Scales of Infant Development (original version 1969); MDI, mean developmental index (cognitive score); PDI, psychomotor develop-
mental index (motor score); NDI, non-verbal developmental index; WWPA, Werry-Weiss Peters Activity Scale; SBIS, Stanford-Binet Intellec-
tual Scale; KABC-A, Kaufman Assessment Battery for Children, achievement component (tests the acquired knowledge of fact); RATC,
Robert’s Apperception Test for Children (tests the child’s perception of common interpersonal situations); CBCL, Child Behavior Checklist;
SON-IQ, Snijders-Oomen Nonverbal Intelligence Test; RDLSC, Reynell Developmental Language Scales (Comprehensive); RDLSE, Reynell
Developmental Language Scales (Expressive); RAKIT, Revision of the Amsterdam Children’s Intelligence Test; IBR, Infant behaviour record;
VSMS, Vineland Social Maturity Scale.
Random effects model
Heterogeneity: I2=0%, tau2=0, p=0.432
Study
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Control group Mean difference
MD
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Figure 1: (a) Weighted mean difference in Mental Developmental Index and (b) Psychomotor Developmental Index of the Bayley Scales of Infant Devel-
opment at age 6 months between methadone-exposed and unexposed infants.
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maintenance methadone in pregnancy is associated with
adverse visual and neurodevelopmental outcomes in infancy
and early childhood, but deficiencies in the existing litera-
ture limit causal inference about harm and factors other
than methadone per se could account for these observa-
tions. Further research into optimal management of opi-
oid-dependent pregnant women is required; future studies
should consider fetal brain development and long term
neurodevelopmental and visual outcomes of the child.
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